Disease or Syndrome – Page 37

BrightGene’s Dual GLP-1/GIP Agonist BGM0504 Shows Promise in Phase 2 Diabetes and Obesity Trials at ADA25

5 months ago talkbio0Tagged ADA25, BGM0504, BrightGene, Diabetes Mellitus, Non-Insulin-Dependent, GLP-1/GIP agonist, Glycosylated hemoglobin A, Obesity, semaglutide, Weight maintenance regimen

BrightGene; BGM0504; GLP-1/GIP agonist; ADA25; Type 2 diabetes; Obesity; Phase 2 clinical trial; weight management; HbA1c reduction; semaglutide; tirzepatide

Amgen Adjusts Phase 3 Dosing for MariTide After Midstage Side Effects Concerns

5 months ago talkbio0Tagged Adverse event, amgen, Clinical Trials, Dosage, Escalation, gastric inhibitory polypeptide receptor, GLP-1 receptor, MariTide, Obesity, Phase 3, Vomiting

Amgen; MariTide; Phase 3; obesity treatment; dose escalation; vomiting; adverse events; clinical trial; GLP-1 receptor; GIP receptor

BrightGene’s BGM0504 Outperforms Novo Nordisk’s Semaglutide in Diabetes Trial, Eyes Showdown with Zepbound

5 months ago talkbio0Tagged BGM0504, BrightGene, Clinical Trials, Diabetes, eli lilly, GLP-1/GIP receptor agonist, Glycosylated hemoglobin A, Nordisk, Obesity, semaglutide, Weight maintenance regimen, Zepbound

BrightGene; diabetes; GLP-1/GIP receptor agonist; BGM0504; semaglutide; Novo Nordisk; Eli Lilly; Zepbound; clinical trial; HbA1c reduction; obesity; weight management

Diabetes and Obesity Drug Boom to Propel Lilly and Novo Nordisk to Pharma Sales Leadership by 2030: Evaluate

5 months ago talkbio0Tagged CagriSema, Diabetes, eli lilly, Evaluate report, Mounjaro, Nordisk, Obesity, Ozempic, Pharmaceutical Sales, semaglutide, tirzepatide, top-selling drugs, Wegovy, Zepbound

diabetes; obesity; pharmaceutical sales; Eli Lilly; Novo Nordisk; Evaluate report; top-selling drugs; tirzepatide; semaglutide; Mounjaro; Zepbound; Ozempic; Wegovy; CagriSema; 2030 forecast

Vertex’s Islet Cell Therapy Shows Dramatic Reduction in Dangerous Low Blood Sugar Levels in Type 1 Diabetes Trial

5 months ago talkbio0Tagged Cell Therapy, Diabetes Mellitus, Insulin-Dependent, Endogenous, Hypoglycemia, Insulin, islet, Stem Cell Therapy, zimislecel

Vertex; islet cell therapy; zimislecel; Type 1 diabetes; hypoglycemia; phase 1/2 trial; endogenous insulin; stem cell therapy

CHMP Recommends Five New Drugs and Reviews Eli Lilly’s Kisunla

5 months ago talkbio0Tagged Biosimilars, CHMP, eli lilly, Hyperphosphatemia (disorder), Kisunla, Multiple Acyl Coenzyme A Dehydrogenase Deficiency, Myopia, regulatory review

CHMP; EMA; new drug approvals; Eli Lilly; Kisunla; biosimilars; hyperphosphatemia; myopia; March 2025; regulatory review

Zealand Pharma’s Dual GLP-1/GLP-2 Agonist Dapiglutide Shows Promising 11.6% Weight Loss at 28 Weeks

5 months ago talkbio0Tagged Clinical Trials, Dapiglutide, Glucagon-Like Peptide 1, Glucagon-Like Peptide 2, Obesity, Safety, Weight Loss, Zealand Pharma

Zealand Pharma; dapiglutide; GLP-1; GLP-2; weight loss; obesity; phase 1b trial; clinical trial; dual agonist; safety

Recent Developments in Immune Profiling for Early Immuno-Oncology Trials

5 months ago talkbio0Tagged Artificial Intelligence, Biological Markers, Clinical Trials, Discover, immune profiling, immuno-oncology, Immunotherapy, microenvironment, multi-omic strategies, Neoplasms, Precision Medicine, spatial proteomics

immune profiling; immuno-oncology; clinical trials; AI in immunotherapy; multi-omic strategies; tumor microenvironment; spatial proteomics; biomarker discovery; personalized medicine

FDA Grants Dupixent (Dupilumab) Eighth Approval: Now Cleared for Bullous Pemphigoid

5 months ago talkbio0Tagged Approved, Autoimmune Diseases, Bullous pemphigoid, Drugs, Orphan, dupilumab, Dupixent, Priority Review, Regeneron, sanofi, type 2 inflammation, United States Food and Drug Administration

Dupixent; Dupilumab; Sanofi; Regeneron; bullous pemphigoid; FDA approval; type 2 inflammation; autoimmune disease; priority review; orphan drug

Regeneron Leads $66M Series B for Actio Biosciences’ Rare Disease Therapeutics

5 months ago talkbio0Tagged ABS-0871, ABS-1230, Actio, Biosciences, Charcot-Marie-Tooth Disease, Clinical Trials, Drugs, Orphan, Epilepsy, Infrequent, Inhibitor, KCNT1 gene, Regeneron, Series B financing, TRPV4 protein, human

Regeneron; Actio Biosciences; rare diseases; Series B financing; KCNT1 inhibitor; TRPV4 inhibitor; ABS-1230; ABS-0871; Charcot-Marie-Tooth disease; epilepsy; orphan drug; clinical trials